L Kager1, S Bielack. 1. Abteilung für Kinder- und Jugendheilkunde, St. Anna Kinderspital, Medizinische Universität Wien, Wien, Österreich.
Abstract
BACKGROUND: Osteosarcoma and Ewing sarcoma are the most common chemosensitive sarcomas of the bone. AIM: Development in chemotherapeutic concepts as well as current and future treatment strategies in osteosarcoma and Ewing sarcoma are presented. METHODS: A PubMed search for "Osteosarcoma" and "Ewing sarcoma" was performed, and pertinent results were summarized. RESULTS: In both osteosarcoma and Ewing sarcoma, outcomes achieved with multimodal treatment concepts combining conventional chemotherapy and local treatment have reached a plateau of about 70% for 5-year survival rates. DISCUSSION: Improved insights into the molecular biology and genetics of the diseases as well as insights into the interactions between sarcoma cells and the micro-environment and the immune system are necessary to identify novel therapeutic targets in bone sarcomas. Because of the rarity of the diseases, multinational cooperation is essential to evaluate novel therapies in prospective randomized trials.
BACKGROUND:Osteosarcoma and Ewing sarcoma are the most common chemosensitive sarcomas of the bone. AIM: Development in chemotherapeutic concepts as well as current and future treatment strategies in osteosarcoma and Ewing sarcoma are presented. METHODS: A PubMed search for "Osteosarcoma" and "Ewing sarcoma" was performed, and pertinent results were summarized. RESULTS: In both osteosarcoma and Ewing sarcoma, outcomes achieved with multimodal treatment concepts combining conventional chemotherapy and local treatment have reached a plateau of about 70% for 5-year survival rates. DISCUSSION: Improved insights into the molecular biology and genetics of the diseases as well as insights into the interactions between sarcoma cells and the micro-environment and the immune system are necessary to identify novel therapeutic targets in bone sarcomas. Because of the rarity of the diseases, multinational cooperation is essential to evaluate novel therapies in prospective randomized trials.
Authors: D Andreou; S S Bielack; D Carrle; M Kevric; R Kotz; W Winkelmann; G Jundt; M Werner; S Fehlberg; L Kager; T Kühne; S Lang; M Dominkus; G U Exner; J Hardes; A Hillmann; V Ewerbeck; U Heise; P Reichardt; P-U Tunn Journal: Ann Oncol Date: 2010-10-28 Impact factor: 32.976
Authors: M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick Journal: N Engl J Med Date: 1986-06-19 Impact factor: 91.245
Authors: Stefan Bielack; Herbert Jürgens; Gernot Jundt; Matthias Kevric; Thomas Kühne; Peter Reichardt; Andreas Zoubek; Mathias Werner; Winfried Winkelmann; Rainer Kotz Journal: Cancer Treat Res Date: 2009
Authors: Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser Journal: N Engl J Med Date: 2003-02-20 Impact factor: 91.245
Authors: G Grignani; E Palmerini; P Dileo; S D Asaftei; L D'Ambrosio; Y Pignochino; M Mercuri; P Picci; F Fagioli; P G Casali; S Ferrari; M Aglietta Journal: Ann Oncol Date: 2011-04-28 Impact factor: 32.976
Authors: Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Sven Bilke; Raphaela Schwentner; Fan Yang; Maximilian Kauer; Gunhild Jug; Robert L Walker; Sean Davis; Yuelin J Zhu; Marbin Pineda; Paul S Meltzer; Heinrich Kovar Journal: Genome Res Date: 2013-08-12 Impact factor: 9.043